AmtixBio

본문 바로가기
사이트 내 전체검색
KOR
ENG
KOR
ENG
  • HOME
  • /
  • ABOUT US
  • /
  • HISTORY

HISTORY

OVERVIEW CEO MESSAGE HISTORY ORGANIZATION CHART

Company History

2024
  • Jul. KOSDAQ IPO, Request for listing
  • Jun. KOSDAQ IPO, Tech. Evaluation
  • Feb. ATB1651, Approved for Onychomycosis treatment clinical phase2 IND (New Zealand)
  • Feb. SAMH-Dermal filler, GMP certification for export of (MFDS)
  • Jan. ATB1651, Onychomycosis treatment clinical phase1 Completion
2023
  • Jul. ATB1606, KOR-CH, Global research cooperation project
  • Jul. ATB1606, Selection of the National New Drug Development Project
  • May. SAMH-Dermal filler, Certification of export authorization (MFDS)
  • Dec. Investment contract with DAESANG Holdings
2022
  • Aug. ATC0001, Selection of national project for invasive multi drug resistant candidiasis
2021
  • Aug. ATB1651, Domestic patent registration
  • Jun. Series C Funding
  • Dec. ATB1651, Onychomycosis treatment clinical phase1 contract (New Zealand, Novotech)
  • Nov. ATB1651, Journal of Medicinal Chemistry (JMC) (IF 8.0) Publishing papers and selecting cover papers
  • Jan. SAMH, GMP facility completion
2020
  • May. Establishment AMTIXBIO AUSTRALIA PTY LTD
  • Mar. ATB1651, Nature Communications(IF17.7) paper published
  • Feb. SAMH, GMP Facility Break ground
2019
  • Feb. Series B Funding
  • Feb. Ambling Brand Launch
2018
  • May. ATB1651, preclinical contract for Antimicrobial New Drug GLP (Charles River)
2017
  • May. Series A Funding
  • Apr. Certification of venture company
2016
  • Jul. Establishment of R&D center
  • May. Test
2015
  • May. Incorporation

회원로그인

회원가입
Headquarters/Laboratory:
Room A-801,802,826,828,829,830, Misa-daero 540, Hanam-si, Gyeonggi-do
GMP:
Room 901,902,903,904,1304, Hanam-daero 947 Hanam-si, Gyeonggi-do
Branch:
Room 606, 2-dong, 61, Madeul-ro 13-gil, Dobong-gu, Seoul (Chang-dong, Seed Cube Chang-dong)
Copyright (c) AmtixBio Corp, All Rights Reserved.